Search Results

SOTIO Announces First Patient Dosed in Phase 1 Clinical Study of SOT201 for Patients with Solid Tumors

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced the dosing of the first patient in its Phase 1, first-in-human clinical trial evaluating SOT201, a next-generation PD-1-targeting immunocytokine.

May 28, 2024

·

2 min read

Genetown

SOTIO Presents Overview of DUET-01 Phase 1/2 Study at ASCO Annual Meeting

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, will present on June 1, 2024 (Developmental Therapeutics—Immunotherapy session) a Trial-in-Progress poster on the first-in-human DUET-01 Phase 1/2 study at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 23, 2024

·

2 min read

Drug Development

SOTIO to Present Poster on DUET-01 Clinical Trial at 2024 ASCO Annual Meeting

SOTIO Biotech announced it will present a Trial-in-Progress poster on the DUET-01 Phase 1/2 study of BOXR1030 at the 2024 American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4, 2024, in Chicago, IL.

April 24, 2024

·

2 min read

Genetown

SOTIO Presents New Preclinical Data on Enhanced CAR T-Cell Therapies at AACR Annual Meeting

SOTIO Biotech today announced it will present new preclinical data at the American Association for Cancer Research (AACR) Annual Meeting taking place April 5-10, 2024, in San Diego, California.

March 12, 2024

·

2 min read

SOTIO Presents Data on SOT201 Immunocytokine and Other Programs at SITC Annual Meeting

SOTIO Biotech today announced it will be presenting new preclinical data at the Society for Immunotherapy of Cancer’s 38th Annual Meeting taking place November 1-5, 2023 in San Diego, California.

October 31, 2023

·

2 min read

SOTIO Provides Update on Interim Data from Clinical Trials of Nanrilkefusp Alfa

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will discontinue the currently ongoing clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab.

October 13, 2023

·

3 min read

SOTIO Further Expands Next-Generation ADC Platform with License to Synaffix’s ADC Technology

SOTIO, a clinical-stage immuno-oncology company owned by PPF Group, announced a license and option agreement with Synaffix B.V., a Lonza company, to develop next-generation antibody-drug conjugates for the treatment of solid tumors.

October 16, 2023

·

5 min read

Drug Development

SOTIO Announces First Patients Dosed in Two Combination Arms of CLAUDIO-01 Study Evaluating SOT102 in First-Line Gastric and Pancreatic Cancer

SOTIO Biotech announced today that it has dosed the first patients in the combination therapy arms of its Phase 1/2 CLAUDIO-01 trial.

October 11, 2023

·

3 min read

Drug Development

SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group,announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.

January 19, 2023

·

4 min read

Business

BioSpace Movers & Shakers: SOTIO, Voyager, Nutcracker and More

Biopharma and life science companies added changes to their leadership teams this week, with Cara Therapeutics, SOTIO Biotech, Agenus, and more filling several C-suite positions.

September 15, 2022

·

6 min read

·

Alex Keown